Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Pharming Group’s Q3 2026 revenue rose 21% year over year to US$117.6 million, exceeding market expectations, while operating profit increased 89% to US$29.9 million. RUCONEST revenue grew 14% to US$93.8 million and Joenja revenue rose 58% to US$23.8 million. The company narrowed its 2026 revenue guidance to US$380–390 million from US$375–395 million and reported positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation.

Analysis

The earnings quality is better than the headline growth alone suggests, but the guidance signal is more neutral: the revised range narrows around the same midpoint, so management has improved confidence rather than raised the annual bar. That may cap immediate multiple expansion unless the call supplies stronger Q4 visibility. Operating leverage is encouraging, but one quarter does not establish a durable margin trajectory.

The key mix shift is Joenja: it is now roughly one-fifth of quarterly revenue, making its launch execution and label expansion increasingly relevant to the valuation. The counterweight is Ruconest’s seasonal inventory contribution. If shipments outran underlying patient demand, subsequent channel normalization could obscure the trend and leave the older product carrying more of the near-term earnings burden than the growth rate implies. Q3 operating cash generation should not be annualized: year-to-date operating cash flow is lower than the quarter alone, flagging first-half cash use and/or working-capital timing that merits reconciliation.

Over the next 1–3 months, the November CVID readout is the principal binary catalyst. A positive result could broaden the addressable population, but topline claims need scrutiny for endpoint quality, durability, safety, and a credible development path. Over 6–18 months, pediatric and international Joenja launches can diversify revenue, with uptake dependent on reimbursement and specialist adoption. The press release is preliminary and unaudited; verify launch economics, cash-flow drivers, and full-year product-level outlook on the call. Contrarian point: strong growth may be priced as a clean inflection, while unchanged midpoint guidance and seasonal inventory leave room for a sell-the-news response.

Key Decisions for Investors

• Do not chase the initial earnings reaction solely on the revenue beat. Treat the unchanged guidance midpoint as a check on near-term upside; use the conference call to test whether management sees demand or only better visibility.
• For a 1–3 month catalyst position, consider a small, defined-risk long PHAR only if the November CVID data are not already fully reflected in the share price. Require interpretable efficacy and safety detail; reduce or exit if the readout is delayed, ambiguous, or accompanied by a weaker commercial outlook.
• Monitor Ruconest reorder patterns and inventory/channel commentary alongside Joenja launch and reimbursement progress. A reversal in Ruconest demand or slowing Joenja uptake would falsify the diversification thesis and argue against adding.
• Reconcile the gap between strong quarterly and weaker year-to-date operating cash generation: request working-capital detail and cash-flow guidance. If Q3 reflects timing rather than sustainable cash generation, discount the quarter’s operating-profit improvement.